StitchTrade1

StitchTrade1
StitchTrade1 Sep 18, 15 8:33 AM

InspireMD continues to maintain a focus on its intellectual property portfolio, expanding coverage for its proprietary MicroNetTM technology, CGuardTM Embolic Prevention System for the treatment of carotid artery disease, and MGuardTM for coronary applications, in addition to several pending applications directed to its neurovascular and peripheral vascular platforms. The issuance of these two patents provides further support for these pending therapies and applications. To-date, the Company’s p

StitchTrade1
StitchTrade1 Sep 18, 15 8:34 AM

To-date, the Company’s patent rights in the United States include 4 issued patents and 10 pending applications. Foreign patent rights include 13 issued patents focused in Israel, Canada, and China, and 16 pending patent applications.

Join now or log in to leave a comment